Predictive clinical baseline factors for successful down-titration
Predictive factor | OR | 95% CI | Pseudo R2 | Prob>χ2 |
---|---|---|---|---|
RF (negative/positive) | 1.3 | 0.30 to 5.57 | 0.0018 | 0.72 |
Anti-CCP (negative/positive) | 0.7 | 0.16 to 3.18 | 0.0035 | 0.64 |
Age (years) | 1.0 | 0.95 to 1.05 | 0.0000 | 0.98 |
Sex (male/female) | 1.1 | 0.36 to 3.51 | 0.0007 | 0.83 |
Smoking (no/yes) | 5.3 | 0.59 to 46.6 | 0.0454 | 0.08 |
Disease duration (years) | 0.9 | 0.86 to 1.01 | 0.0392 | 0.10 |
DAS28 at start | 0.6 | 0.26 to 1.21 | 0.0345 | 0.12 |
Duration of infliximab therapy (years) | 0.9 | 0.73 to 1.15 | 0.0081 | 0.46 |
Methotrexate use (no/yes) | 1.3 | 0.40 to 4.38 | 0.0029 | 0.65 |
DMARD use (no/yes) | 1.0 | 0.25 to 4.28 | 0.0000 | 0.95 |
Patient's belief on successful down-titration (no/yes) | 2.4 | 0.71 to 7.76 | 0.0292 | 0.16 |
Anti-CCP, anti-cyclic citrullinated peptide; DAS28, 28-joint disease activity score; DMARD, disease-modifying antirheumatic drugs, RF, rheumatoid factor.